Table 2.
Univariate analysis of factors associated with OS of EHC patients.
| Variables | Univariate analysis | |
|---|---|---|
| HR (95% CI) | p value | |
| Gender (male vs. female) | 1.027 (0.736–1.433) | 0.876 |
| Age (high vs. low) | 1.049 (0.759–1.449) | 0.771 |
| Location (DCCA vs. HCCA) | 0.826 (0.585–1.168) | 0.279 |
| CA19-9 (high vs. low) | 1.991 (1.225–3.234) | 0.005 |
| CEA (high vs. low) | 1.131 (0.804–1.591) | 0.478 |
| ALT (high vs. low) | 1.225 (0.782–1.921) | 0.376 |
| AST (high vs. low) | 1.188 (0.831–1.697) | 0.345 |
| ALP (high vs. low) | 1.229 (0.785–1.923) | 0.368 |
| GGT (high vs. low) | 1.401 (0.791–2.483) | 0.248 |
| TBIL (high vs. low) | 1.914 (1.334–2.747) | <0.001 |
| DBIL (high vs. low) | 1.370 (0.976–1.924) | 0.069 |
| ALB (high vs. low) | 0.764 (0.550–1.063) | 0.110 |
| PT-INR (high vs. low) | 1.182 (0.826–1.691) | 0.360 |
| NC (high vs. low) | 1.438 (1.032–2.003) | 0.032 |
| LC (high vs. low) | 0.612 (0.381–0.984) | 0.043 |
| PLT (high vs. low) | 0.878 (0.594–1.298) | 0.514 |
| CRP (high vs. low) | 1.189 (0.823–1.718) | 0.356 |
| PTBS + 125I vs. PTBS | 0.280 (0.193–0.406) | <0.001 |
HCCA hilar cholangiocarcinoma, DCCA distal cholangiocarcinoma, CA19-9 carbohydrate antigen 19-9, CEA carcino-embryonic antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transpeptidase, TBIL total bilirubin, DBIL direct bilirubin, ALB albumin, PT-INR prothrombin time-international normalized ratio, NC neutrophil count, LC lymphocyte count, PLT platelet count, CRP c-reactive protein, PTBS percutaneous transhepatic biliary stenting.